Northwest Biotherapeutics (NWBO) Stock Statistics & Valuation Metrics

Northwest Biotherapeutics has a market cap or net worth of $363.60M. The enterprise value is ―.

Northwest Biotherapeutics has 1,540,682,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Northwest Biotherapeutics’s return on equity (ROE) is 1.06 and return on invested capital (ROIC) is 972.34%.

The current PE Ratio of Northwest Biotherapeutics is ―. Northwest Biotherapeutics’s PEG ratio is -0.21.

In the last 12 months, Northwest Biotherapeutics had revenue of 1.38M and earned -83.78M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was -128.15M and capital expenditures 638.00K, giving a free cash flow of -127.32M billion.

Northwest Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Northwest Biotherapeutics upcoming earnings date is ―, ―.

Northwest Biotherapeutics as a current ratio of 0.06, with Debt / Equity ratio of -80.89%

In the past 12 months, Northwest Biotherapeutics has paid 0.00 in taxes.

Northwest Biotherapeutics EV to EBITDA ratio is -5.44, with an EV/FCF ratio of -6.90.

Northwest Biotherapeutics has $4.56M in cash and marketable securities with $77.05M in debt, giving a net cash position of -$72.49M billion.

Gross margin is 78.66%, with operating margin of -4812.45%, and net profit margin of -6062.08%.

The average price target for Northwest Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―